Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment
- PMID: 27431279
- DOI: 10.1007/s10072-016-2670-2
Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment
Abstract
Botulinum toxin A (BoNT-A) injection is one of the most widely used methods for hemifacial spasm (HFS) with high efficacy in controlling spasm. However, it is still unknown if esthetic symmetry could be desired as the spasm was controlled by BoNT-A therapy. The purpose of this study is to clarify the facial asymmetric characteristics of HFS patients and if the asymmetry could be amended by BoNT-A injection in the abnormal side. In this prospective analysis, HFS patients were enrolled, who received hemifacial BoNT-A injection and completed follow-up at weeks 2-4. Self-reported improvement and negative influence of facial asymmetry in social life were documented. Facial asymmetry was assessed by the Sunnybrook facial grading system (SFGS) and a new scale created by our clinic-the Symmetry Scale for Hemifacial Spasm (SSHS). Thirty-eight patients were eligible for analysis. Among them, 34 patients (89 %) had marked improvement in spasm after BoNT-A injection. After BoNT-A injection, SFGS showed an improvement of synkinesis (p = 0.01). And SSHS showed an amelioration of resting symmetry in lower face after treatment (p < 0.05). However, SFGS showed a deterioration of voluntary movement in lower face after treatment (p < 0.01). In addition, a deterioration of voluntary movement in upper face and lower face was found in SSHS after treatment (p < 0.01). SSHS composite score showed a deterioration after BoNT-A injection (p = 0.01). In conclusions, BoNT-A was effective in controlling spasm and synkinesis of HFS and improved resting symmetry in lower face, but facial symmetry of voluntary movement deteriorated after hemifacial BoNT-A injection.
Keywords: Botulinum toxin A; Facial asymmetry; Hemifacial spasm.
Similar articles
-
Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry.J Neurol. 2018 Sep;265(9):2097-2105. doi: 10.1007/s00415-018-8960-2. Epub 2018 Jul 9. J Neurol. 2018. PMID: 29987587 Clinical Trial.
-
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes.J Neural Transm (Vienna). 2025 Jan;132(1):23-38. doi: 10.1007/s00702-024-02821-y. Epub 2024 Aug 23. J Neural Transm (Vienna). 2025. PMID: 39174752 Review.
-
Subjective and Objective Measures in the Treatment of Hemifacial Spasm With OnabotulinumtoxinA.Ophthalmic Plast Reconstr Surg. 2016 Mar-Apr;32(2):133-7. doi: 10.1097/IOP.0000000000000443. Ophthalmic Plast Reconstr Surg. 2016. PMID: 25811161
-
Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial.Ann Med. 2025 Dec;57(1):2537921. doi: 10.1080/07853890.2025.2537921. Epub 2025 Jul 25. Ann Med. 2025. PMID: 40712006 Free PMC article. Clinical Trial.
-
Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies.Toxins (Basel). 2021 Dec 9;13(12):881. doi: 10.3390/toxins13120881. Toxins (Basel). 2021. PMID: 34941718 Free PMC article. Review.
Cited by
-
Bibliometric analysis of studies on the treatment of hemifacial spasm.Front Neurol. 2022 Sep 1;13:931551. doi: 10.3389/fneur.2022.931551. eCollection 2022. Front Neurol. 2022. PMID: 36119704 Free PMC article.
-
Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry.J Neurol. 2018 Sep;265(9):2097-2105. doi: 10.1007/s00415-018-8960-2. Epub 2018 Jul 9. J Neurol. 2018. PMID: 29987587 Clinical Trial.
-
Use of Botulinum Toxin in Orofacial Clinical Practice.Toxins (Basel). 2020 Feb 11;12(2):112. doi: 10.3390/toxins12020112. Toxins (Basel). 2020. PMID: 32053883 Free PMC article. Review.
-
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes.J Neural Transm (Vienna). 2025 Jan;132(1):23-38. doi: 10.1007/s00702-024-02821-y. Epub 2024 Aug 23. J Neural Transm (Vienna). 2025. PMID: 39174752 Review.
-
Botulinum toxin A treatment in facial palsy synkinesis: a systematic review and meta-analysis.Eur Arch Otorhinolaryngol. 2023 Apr;280(4):1581-1592. doi: 10.1007/s00405-022-07796-8. Epub 2022 Dec 22. Eur Arch Otorhinolaryngol. 2023. PMID: 36544062
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical